Post by Viralgen

While both wild type and novel adeno-associated virus (AAV) capsids have had clinical success, there’s a current push to improve transduction efficiency, reduce immunogenicity, and enhance tissue targeting by producing and enhancing novel capsids.   Yet pursuing those improvements can introduce additional manufacturing complexity – and require the reassessment and adaptation of existing analytical methods. Through a webinar hosted by Cell & Gene , our team from Viralgen and our fellow panelists from GenoSafe and Dark Horse Consulting Group Inc. will discuss what we’ve learned while addressing key challenges in novel capsid manufacturing, including considerations for analytical testing and regulatory guidance.   Cell & Gene #Webinar Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsids June 2, 2026 | 11:00 AM ET Use the link below to save your spot: https://lnkd.in/dDVWpw3M Andy Holt Jacob Smith Laurence Jeanson Sabrina Triffault (Donnou) Daniel Lourenco Jacob Staudhammer #aav #cellandgene #cellandgenetherapy #cgt #biotech